CLINICAL TRIALS AND OBSERVATIONS High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
نویسندگان
چکیده
1Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany; 2Department of Hematology, University Hospital, Leipzig, Germany; 3Center for Bone Marrow Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany; 4Department of Medicine II, University Hospital, Mainz, Germany; 5University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 6Hematology/Oncology, Medizinische Hochschule, Hannover, Germany; 7Department of Medicine II, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 8Internal Medicine II, Klinikum Oldenburg, Hematology/Oncology, Oldenburg, Germany; 9Center for Internal Medicine, Department of Hematology, University Hospital, Essen, Germany; 10Department for Hematology/Oncology, University Hospital, Düsseldorf, Germany; 11Department of Medicine I, Carl Gustav Carus University, Dresden, Germany; 12Department of Hematology and Oncology, HELIOS Klinikum Berlin Buch, Berlin, Germany; 13Hematology/Oncology, University Hospital, Regensburg, Germany; 14Internal Medicine A, University Hospital, Münster, Germany; 15Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; and 16Hematology/Oncology, Kliniken Essen Süd, Essen-Werden, Germany
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Cancer and Leukemia Group B (CALGB) Statistical Center, Duke University Medical Center, Durham, NC; 3Stanford University School of Medicine, Stanford, CA; 4Arizona Cancer Center, Tucson, AZ; 5Duke University Medical Center, Durham, NC; 6University of North Carolina, Chapel Hill, NC; 7Fred Hutchinson Cancer Research Cent...
متن کاملBrentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
IMPORTANCE The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis
Allogeneic stem cell transplantation (SCT) is frequently considered as treatment for relapsed childhood acute lymphoblastic leukemia (ALL). For patients without a matched sibling donor, SCT from unrelated donors (UD-SCT) has been increasingly performed during the past years. However, UD-SCT–related mortality and morbidity is still considerable, and the question remains as to which patients are ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Nonmyeloablative stem cell transplantation in patients with follicular lymphoma has been designed to exploit the graftversus-lymphoma immunity. The longterm effectiveness and toxicity of this strategy, however, is unknown. In this prospective study, we analyzed our 8-year experience. Patients received a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
Donor lymphocyte infusions (DLIs) induce potent graft versus tumor (GVT) effects for relapsed chronic myelogenous leukemia (CML) after allogeneic stem cell transplantation (SCT) but are disappointing for other diseases. Disease resistance can occur if donor T cells are not appropriately activated in vivo. Ex vivo T-cell activation might overcome diseaseinduced anergy and augment GVT activity. W...
متن کامل